GeneDx Holdings (WGS)
NASDAQ:WGS
Want to see WGS full AI Analyst Report?
Earnings Data
Report Date
Aug 17, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.19Last Year’s EPS
0.5Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a balanced picture: strong operational momentum (34% volume growth, 27% exome/genome revenue growth, healthy ~69% adjusted gross margin, large proprietary dataset, new commercial products and expanded sales coverage) tempered by near-term execution and mix challenges (approximately $12M revenue shortfall in Q1 driven by lower blended ARR and $6.5M non-core misses), a significant Fabric impairment (~$31.3M), and a 12% reduction to prior full-year revenue expectations. Management laid out concrete remediation actions — tighter channel/revenue-cycle management, cost recalibration ($25M OpEx reduction), and focused commercial execution — and provided updated guidance that emphasizes line-of-sight growth and a pathway back to adjusted profitability in 2026, with further ARR improvement expected over multiple quarters as payer coverage and collections improve.Company Guidance
Robust Volume Growth
Test result volume grew 34% year-over-year to 27,488 tests in Q1, demonstrating strong demand across foundational and expansion markets.
Exome & Genome Revenue Momentum
Exome and genome revenue was $90.6 million, up 27% year-over-year, reflecting successful penetration of higher-content tests despite mix dynamics.
Large and Differentiated Data Asset
GeneDx reported a contactable database with >2.5 million patients, >1 million exomes and genomes, and >8 million matched phenotypic profiles — a strategic moat for interpretation, payer engagement, and biopharma partnerships.
Healthy Gross Margins and Clear Path to Profitability
Adjusted gross margin was 69% in Q1 and management reiterated expected adjusted gross margins of ~70% for 2026, with a commitment to return to adjusted profitability by year-end and meaningful margin/profit expansion into 2027.
Commercial & Product Initiatives
Launched Reflex offering (Feb) to balance genome adoption and unit economics; expanded sales teams across specialists (≈75 reps), general pediatrics (≈50 reps), NICU (≈10 reps) and prenatal (≈10 reps) to accelerate adoption in key channels, and reported encouraging NICU traction and early general pediatrics ordering.
Updated Guidance with Line-of-Sight Execution
Revised full-year 2026 revenue guidance to $475M–$490M, with at least 30% exome & genome volume growth (~126,400 tests) and at least 20% exome & genome revenue growth; Q2 guidance set to $110M–$112M total revenue and ~30,000 exome/genome tests, indicating management confidence in near-term momentum.
Cost Discipline and Focused Investment
Taken decisive OpEx actions including a $25 million reduction/recalibration of planned spend for 2026 to prioritize three levers: grow utilization, optimize unit economics (ARR & COGS), and deliver leading products at scale.
WGS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
WGS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 04, 2026 | $67.93 | $34.51 | -49.20% |
Feb 23, 2026 | $82.06 | $87.08 | +6.12% |
Oct 28, 2025 | $130.66 | $137.47 | +5.21% |
Jul 29, 2025 | $84.91 | $91.78 | +8.09% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does GeneDx Holdings (WGS) report earnings?
GeneDx Holdings (WGS) is schdueled to report earning on Aug 17, 2026, After Close (Confirmed).
What is GeneDx Holdings (WGS) earnings time?
GeneDx Holdings (WGS) earnings time is at Aug 17, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is WGS EPS forecast?
WGS EPS forecast for the fiscal quarter 2026 (Q2) is -0.19.